A — Mab A Case Study In Bioprocess Development [upd]

This transition is epitomized by Enzene's platform. By 2025, the company had achieved its stated target of reducing mAb production costs to less than $40 per gram . For context, other continuous processes average $80–100 per gram, while fed-batch can run from $150 to $500 per gram . The economic benefits are substantial, with FCCM technology achieving yields tenfold greater than conventional batch manufacturing, leading to a cost of goods sold reduction as high as 40–50% . These savings are not theoretical: four mAbs have already been commercialized using this technology.

Acidic and basic species analyzed using ion-exchange chromatography (IEX) or iso-electric focusing (cIEF).

Using a approach, developers screened various basal and feed media. Optimization focused on maximizing specific productivity ( A Mab A Case Study In Bioprocess Development

This content is suitable for a bioprocess engineering blog, a technical whitepaper, or an educational slide deck.

, protecting downstream chromatography columns from fouling. Capture Step: Protein A Chromatography This transition is epitomized by Enzene's platform

Adjusting asparagine concentration directly decreased undesired high-mannose glycan structures. Bioreactor Scale-Up

The case study concludes with a summary of key performance indicators (KPIs) for Mab-X: The economic benefits are substantial, with FCCM technology

Development begins with the Target Product Profile (TPP) , which outlines the desired clinical performance. The study identified key attributes that must be controlled, including: